---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-112674"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:39:50.370094+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# enGene achieves target enrollment of 100 patients in Phase 2 LEGEND trial for detalimogene in BCG-unresponsive NMIBC

## Summary
- Target enrollment of 100 patients reached in Cohort 1 of Phase 2 LEGEND trial.
- Trial evaluates detalimogene voraplasmid in high-risk, BCG-unresponsive NMIBC with CIS ± papillary disease.
- Corporate presentation updated September 3, 2025; news release issued same day.

## SEC filing metadata
- accession: 0000950170-25-112674
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000095017025112674/0000950170-25-112674-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000095017025112674/engn-20250903.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-112674
- JSON: https://secwatch.observer/filing/0000950170-25-112674.json
- Plain text: https://secwatch.observer/filing/0000950170-25-112674.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.